ORG Partners LLC Sells 160 Shares of Align Technology, Inc. (NASDAQ:ALGN)

ORG Partners LLC lessened its position in shares of Align Technology, Inc. (NASDAQ:ALGN) by 39.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 242 shares of the medical equipment provider’s stock after selling 160 shares during the quarter. ORG Partners LLC’s holdings in Align Technology were worth $66,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the company. Cerity Partners LLC grew its holdings in shares of Align Technology by 21.2% during the 4th quarter. Cerity Partners LLC now owns 100,510 shares of the medical equipment provider’s stock worth $27,539,000 after purchasing an additional 17,556 shares in the last quarter. Impax Asset Management Group plc grew its holdings in shares of Align Technology by 65.0% during the 4th quarter. Impax Asset Management Group plc now owns 114,369 shares of the medical equipment provider’s stock worth $31,337,000 after purchasing an additional 45,070 shares in the last quarter. Sequoia Financial Advisors LLC grew its holdings in shares of Align Technology by 67.9% during the 4th quarter. Sequoia Financial Advisors LLC now owns 1,679 shares of the medical equipment provider’s stock worth $460,000 after purchasing an additional 679 shares in the last quarter. HBK Sorce Advisory LLC grew its holdings in shares of Align Technology by 26.1% during the 4th quarter. HBK Sorce Advisory LLC now owns 1,597 shares of the medical equipment provider’s stock worth $438,000 after purchasing an additional 331 shares in the last quarter. Finally, International Assets Investment Management LLC acquired a new stake in shares of Align Technology during the 4th quarter worth approximately $141,140,000. Institutional investors and hedge funds own 88.43% of the company’s stock.

Insider Buying and Selling at Align Technology

In other news, Director Joseph Lacob sold 10,000 shares of the company’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $313.01, for a total transaction of $3,130,100.00. Following the completion of the transaction, the director now directly owns 146,994 shares of the company’s stock, valued at $46,010,591.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Joseph Lacob sold 10,000 shares of the company’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $313.01, for a total transaction of $3,130,100.00. Following the completion of the transaction, the director now directly owns 146,994 shares of the company’s stock, valued at $46,010,591.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Emory Wright sold 2,524 shares of the company’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $287.45, for a total value of $725,523.80. Following the transaction, the executive vice president now directly owns 709 shares of the company’s stock, valued at $203,802.05. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 27,524 shares of company stock valued at $8,403,924. Company insiders own 0.72% of the company’s stock.

Align Technology Trading Down 3.2 %

NASDAQ:ALGN opened at $304.74 on Tuesday. Align Technology, Inc. has a 1 year low of $176.34 and a 1 year high of $413.20. The stock has a market cap of $22.93 billion, a price-to-earnings ratio of 52.36, a PEG ratio of 5.67 and a beta of 1.65. The stock has a 50-day moving average price of $311.97 and a two-hundred day moving average price of $269.75.

Align Technology (NASDAQ:ALGN) last posted its earnings results on Wednesday, January 31st. The medical equipment provider reported $1.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.78 by $0.13. Align Technology had a return on equity of 13.88% and a net margin of 11.52%. The firm had revenue of $956.73 million during the quarter, compared to analysts’ expectations of $928.57 million. Sell-side analysts forecast that Align Technology, Inc. will post 7.65 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Stifel Nicolaus boosted their price target on Align Technology from $340.00 to $350.00 and gave the company a “buy” rating in a research note on Friday, March 15th. UBS Group boosted their price target on Align Technology from $280.00 to $320.00 and gave the company a “neutral” rating in a research note on Monday. The Goldman Sachs Group boosted their price target on Align Technology from $197.00 to $225.00 and gave the company a “sell” rating in a research note on Friday, February 2nd. Leerink Partnrs reaffirmed a “market perform” rating on shares of Align Technology in a research note on Monday, February 26th. Finally, Piper Sandler boosted their price target on Align Technology from $335.00 to $355.00 and gave the company an “overweight” rating in a research note on Thursday, March 14th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $339.91.

About Align Technology

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.